Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 301–400 of 1,002
Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence
Libertini, S. J., Tepper, C. G., Rodriguez, V., Asmuth, D. M., Kung, H.-J., & Mudryj, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1072 · Cited by 130
“Several mechanisms may account for AR activation in low levels of androgen: (a) AR mutations that require low levels of androgen; (b) activation of AR by nonsteroid ligands, such as growth factors and cytokines (2); (c) overexpression/amplification of AR or its coactivators (3); (d) locuswide histone transcriptional a…”
Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function
Basak, S., Pookot, D., Noonan, E. J., & Dahiya, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0617 · Cited by 142
“It has been shown that a major mechanism for progression to hormone-refractory androgen-independent prostate cancer is reactivation of the AR (5, 37).”
BackgroundTargeting the adaptive molecular landscape of castration‐resistant prostate cancer
Wyatt, A. W., & Gleave, M. E. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303701 · Cited by 127
“The consequent overexpression of AR in CRPC tissue confers hypersensitivity to low levels of androgen as well as facilitating antagonist to agonist conversion for some first-generation AR antagonists (Chen et al , 2004).”
Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.
Grant, C. M., & Kyprianou, N. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.04 · Cited by 154
“Increased AR expression, elevated intraprostatic androgens and perpetually activated AR signaling in the face of castrate levels of androgens characterize this progression to CRPC (8,9).”
BackgroundAmyloid Precursor Protein Is a Primary Androgen Target Gene That Promotes Prostate Cancer Growth
Takayama, K., Tsutsumi, S., Suzuki, T., Horie‐Inoue, K., Ikeda, K., Kaneshiro, K., Fujimura, T., Kumagai, J., Urano, T., Sakaki, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3633 · Cited by 138
“Androgen receptor (AR) has been revealed to play a critical role in both androgen-dependent and androgen-refractory prostate tumors (2), although the pathogenesis of the disease remains unclear.”
BackgroundMostaghel, E. A., & Nelson, P. S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.003 · Cited by 141
Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W. A., & Nevalainen, M. T. (2016) · Oncotarget · doi:10.18632/oncotarget.12554 · Cited by 144
“In one report, cDNA microarray analysis of CRPC xenograft tumors found that the only change consistently associated with antiandrogen resistance was a modest increase in AR mRNA levels [63].”
BackgroundTumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy
Xu, X., Saw, P. E., Tao, W., Li, Y., Ji, X., Yu, M., Mahmoudi, M., Rasmussen, J., Ayyash, D., Zhou, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01571 · Cited by 127
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
Li, S., Fong, K.-W., Gritsina, G., Zhang, A., Zhao, J. C., Kim, J., Sharp, A., Yuan, W., Aversa, C., Yang, X. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2812 · Cited by 136
“The androgen receptor (AR) is a major driver of the growth of prostate cancer (PCa) (1,2) and aberrant AR signaling remains to play major roles in final-stage castration-resistant prostate cancer (CRPC) that have developed resistance to the second-generation AR antagonist enzalutamide (Enz), or the androgen-biosynthes…”
BackgroundCheng, H., Snoek, R., Ghaidi, F., Cox, M. E., & Rennie, P. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0028 · Cited by 128
“The most potent AR shRNA (Fig. 1) was directed to the ligandbinding domain and is similar to that reported by Chen et al. ( 37 ).”
BackgroundResultInfluentialGenomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Mendiratta, P., Mostaghel, E., Guinney, J., Tewari, A. K., Porrello, A., Barry, W. T., Nelson, P. S., & Febbo, P. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2882 · Cited by 126
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
“Based on previous findings that increased androgen receptor activity is sufficient to bypass the response to androgen receptor antagonists (30), the ability of the direct androgen receptor antagonist Casodex to inhibit androgen-mediated androgen receptor activity in the context of USP22 deregulation was determined.”
Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., & Wang, Z. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0188 · Cited by 126
Wilson, S., Qi, J., & Filipp, F. V. (2016) · Scientific Reports · doi:10.1038/srep32611 · Cited by 126
“Most AR chromatin binding studies were performed in the LNCaP cell line or its sublines 3,4,6,7,9–12 , which are highly sensitive and responsive to androgen stimulation.”
Snoek, R., Cheng, H., Margiotti, K., Wafa, L. A., Wong, C. A., Wong, E. C., Fazli, L., Nelson, C. C., Gleave, M. E., & Rennie, P. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1726 · Cited by 131
“The availability of an in vivo tumor model system for AR knockdown is hindered by the failure of cells depleted of the AR protein to grow as xenografts in mice (8).”
BackgroundLitvinov, I. V., Griend, D. J. V., Antony, L., Dalrymple, S. L., Marzo, A. M. D., Drake, C. G., & Isaacs, J. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603057103 · Cited by 126
miR 488* inhibits androgen receptor expression in prostate carcinoma cells
Sikand, K., Slaibi, J. E., Singh, R., Slane, S. D., & Shukla, G. C. (2011) · International Journal of Cancer · doi:10.1002/ijc.25753 · Cited by 124
Are androgen receptor variants a substitute for the full-length receptor?
Ji, L., der Steen, T. V., & Tindall, D. J. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.13 · Cited by 138
Shiota, M., Yokomizo, A., & Naito, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.07.011 · Cited by 135
“Many studies have shown that the progression of CRPC is associatedwith increased AR expression [36–39].”
BackgroundLi, Y., Wang, Z. P., Kong, D., Murthy, S., Dou, Q. P., Sheng, S., Reddy, G. P. V., & Sarkar, F. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701978200 · Cited by 130
Androgen action in prostate function and disease.
Banerjee, P. P., Banerjee, S., Brown, T. R., & Zirkin, B. R. (2018) · Europe PMC (PubMed Central) · Cited by 178
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development
Azevedo, A. S., Cunha, V., Teixeira, A. L., & Medeiros, R. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i12.384 · Cited by 133
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
Gao, L., Schwartzman, J. A., Gibbs, A., Lisac, R., Kleinschmidt, R., Wilmot, B., Bottomly, D., Coleman, I. M., Nelson, P. S., McWeeney, S. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063563 · Cited by 133
“AR and c-Myc are Concordantly Expressed in Metastatic CRPC Both AR and c-Myc are critical survival pathways in prostate cancer, and expression levels of both AR and c-Myc are commonly increased in human CRPC tumors progressing despite ADT [24,25].”
BackgroundBlueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 157
Schweizer, L., Rizzo, C. A., Spires, T. E., Platero, J. S., Wu, Q., Lin, T.-A., Gottardis, M. M., & Attar, R. M. (2008) · BMC Cell Biology · doi:10.1186/1471-2121-9-4 · Cited by 139
“It has been postulated that increased levels of both the androgen receptor (AR) mRNA and protein are associated with this transition [1-3].”
Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo
Xia, Q., Sung, J., Chowdhury, W., Chen, C.-L., Höti, N., Shabbeer, S., Carducci, M., & Rodriguez, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0487 · Cited by 121
“(34) showed in vitro that androgen receptor amplification alone could result in the development of the androgen-independent phenotype.”
BackgroundSelf-citationChuu, C., Hiipakka, R. A., Fukuchi, J., Kokontis, J. M., & Liao, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3992 · Cited by 121
“(8) reported that a modest increase in AR mRNA was the only change consistently associated with the development of resistance to androgen ablation therapy, and the increase in AR mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage.”
BackgroundXenoestrogen Action in Prostate Cancer: Pleiotropic Effects Dependent on Androgen Receptor Status
Wetherill, Y. B., Fisher, N. L., Staubach, A., Danielsen, M., White, R. D., & Knudsen, K. E. (2005) · Cancer Research · doi:10.1158/0008-5472.54.65.1 · Cited by 137
“resistance to anti-androgen therapy (11).”
Creighton, C. J., Cordero, K. E., Larios, J. M., Miller, R. S., Johnson, M. D., Chinnaiyan, A. M., Lippman, M. E., & Rae, J. M. (2006) · Genome biology · doi:10.1186/gb-2006-7-4-r28 · Cited by 122
“However, when examining two public mRNA profile datasets of LNCaP prostate cancer cells stimulated to profilerate with androgen treatment [27,28], myc was not found to be up-regulated (Chen dataset p = 0.”
BackgroundRegulation of Akt/FOXO3a/GSK-3β/AR Signaling Network by Isoflavone in Prostate Cancer Cells
Li, Y., Wang, Z. P., Kong, D., Li, R., Sarkar, S. H., & Sarkar, F. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802759200 · Cited by 125
Abali, G. K., Alptekin, A., Lewis, M. S., Garraway, I. P., & Cinar, B. (2015) · Nature Communications · doi:10.1038/ncomms9126 · Cited by 128
Takayama, K., Misawa, A., Suzuki, T., Takagi, K., Hayashizaki, Y., Fujimura, T., Homma, Y., Takahashi, S., Urano, T., & Inoue, S. (2015) · Nature Communications · doi:10.1038/ncomms9219 · Cited by 124
Androgen receptor function is modulated by the tissue‐specific AR45 variant
Ahrens‐Fath, I., Politz, O., Geserick, C., & Haendler, B. (2005) · The FEBS Journal · doi:10.1111/j.1432-1033.2004.04395.x · Cited by 119
Ang, J. E., Olmos, D., & Bono, J. S. D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604904 · Cited by 128
“Furthermore, currently approved antiandrogens, such as bicalutamide, hydroxyflutamide and nilutamide, have weak agonistic effects in prostate cancers with mutated or overexpressed AR (”
BackgroundETV1 Is a Novel Androgen Receptor-Regulated Gene that Mediates Prostate Cancer Cell Invasion
Cai, C., Hsieh, C.-L., Omwancha, J., Zheng, Z., Chen, S.-Y., Baert, J.-L., & Shemshedini, L. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0480 · Cited by 120
Androgen regulation of gene expression.
(2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07005-3 · Cited by 117
Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
Nakazawa, M., Antonarakis, E. S., & Luo, J. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0190-1 · Cited by 132
“Among these, alterations involving the AR gene and its products (including AR amplification [92, 58, 14], gain-of-function mutation [86, 82], and overexpression [20]) are the most specific to CRPC.”
BackgroundElevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death
Garcia‐Carbonell, R., Wong, J., Kim, J. Y., Close, L. A., Boland, B. S., Wong, T. L., Harris, P. A., Ho, S. B., Das, S., Ernst, P. B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810584115 · Cited by 125
Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy
Burnstein, K. L. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20460 · Cited by 118
“As discussed above, upregulation of AR can drive progression to androgen-independent prostate cancer [Chen et al., 2004].”
BackgroundAndrogen Receptor and Invasion in Prostate Cancer
Hara, T., Miyazaki, H., Lee, A., Tran, C. P., & Reiter, R. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1929 · Cited by 116
“Recent data showed that increased AR expression is correlated with androgen-refractory tumor growth (8); therefore, we asked whether MDA-I cells still require androgen for their growth by culturing them in normal FBS medium versus androgen-depleted DCC-FBS medium.”
BackgroundSelf-citationSteroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Denmeade, S. R., & Isaacs, J. T. (2010) · The Prostate · doi:10.1002/pros.21196 · Cited by 125
“[21] this cell line,when serially adapted, also grows well at much lower androgen conditions compared to unadapted cells.”
BackgroundInfluentialTindall, D. J., & Rittmaster, R. S. (2008) · The Journal of Urology · doi:10.1016/j.juro.2007.11.033 · Cited by 142
Molecular Subtypes of Prostate Cancer
Arora, K., & Barbieri, C. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0707-9 · Cited by 133
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation
Rasool, R. U., Natesan, R., Deng, Q., Aras, S., Lal, P., Effron, S. S., Mitchell-Velasquez, E., Posimo, J. M., Carskadon, S. L., Baca, S. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0189 · Cited by 133
Signal transduction in prostate cancer progression
GIOELI, D. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 118
Ricciardelli, C., Choong, C. S., Buchanan, G., Vivekanandan, S., Neufing, P. J., Stahl, J., Marshall, V. R., Horsfall, D. J., & Tilley, W. D. (2004) · The Prostate · doi:10.1002/pros.20154 · Cited by 116
“This hypothesis is supported by recent studies of 7 different prostate cancer xenograft models, demonstrating that the AR was the only gene exhibiting consistently increased expression in hormone-refractory disease [16].”
Guerrero, J., Alfaro, I. E., Gómez, F. J., Protter, A. A., & Bernales, S. (2013) · The Prostate · doi:10.1002/pros.22674 · Cited by 135
The lncRNA DRAIC / PCAT29 Locus Constitutes a Tumor-Suppressive Nexus
Sakurai, K., Reon, B. J., Anaya, J., & Dutta, A. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0016-t · Cited by 130
“Several lines of evidence have shown that the androgen receptor (AR) or androgen-responsive pathways are differently activated in the CR cells so that pathways are active in low or absent androgen (1, 2).”
BackgroundEmerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
Cornelison, R., Llaneza, D. C., & Landen, C. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102171 · Cited by 130
“After androgen deprivation therapy, the cells amplify the level of androgen receptor to the point that the levels are too high to stoichiometrically defeat [40].”
BackgroundAndrogen receptor and its splice variants in prostate cancer
Haile, S., & Sadar, M. D. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0766-7 · Cited by 137
“Androgen receptor (AR) is essential for the growth of CRPC in vitro and in xenograft models [1].”
BackgroundYang, X., Guo, Z., Sun, F., Li, W., Alfano, A., Shimelis, H., Chen, M., Brodie, A. M. H., Chen, H., Xiao, Z., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.265124 · Cited by 127
Isaacs, J. T., D’Antonio, J. M., Chen, S., Antony, L., Dalrymple, S. P., Ndikuyeze, G. H., Luo, J., & Denmeade, S. R. (2012) · The Prostate · doi:10.1002/pros.22504 · Cited by 113
“These replication results when combined with the observations that CRPC cells have increased AR [4] and that androgen binding stabilizes AR protein and increases its nuclear retention, [21] provide a rationale for a paradigm shifting approach to CRPC.”
BackgroundInfluentialYamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., Asahi, S., Miki, H., Tasaka, A., & Kusaka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.01.001 · Cited by 123
Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF
Takayama, K., Suzuki, T., Fujimura, T., Yamada, Y., Takahashi, S., Homma, Y., Suzuki, Y., & Inoue, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706076114 · Cited by 116
“However, most of the patients acquire resistance to this therapy and eventually suffer from castration-resistant prostate cancer (CRPC) (2, 3).”
BackgroundTakayama, K., Suzuki, T., Tanaka, T., Fujimura, T., Takahashi, S., Urano, T., Ikeda, K., & Inoue, S. (2018) · Oncogene · doi:10.1038/s41388-017-0095-x · Cited by 116
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 125
Li, B. K., Vasiljevic, A., Dufour, C., Yao, F., Ho, B., Lu, M., Hwang, E. I., Gururangan, S., Hansford, J. R., Fouladi, M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02111-y · Cited by 124
CYP17 inhibition as a hormonal strategy for prostate cancer
Reid, A. H. M., Attard, G., Barrie, E., & Bono, J. S. D. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1237 · Cited by 119
“and activating point mutations that might generate promiscuous ARs”
BackgroundOvercoming Drug Resistance and Treating Advanced Prostate Cancer
Semenas, J., Allegrucci, C., Boorjian, S. A., Mongan, N. P., & Persson, J. L. (2012) · Current Drug Targets · doi:10.2174/138945012802429615 · Cited by 125
“It has been suggested that intrinsic-mechanism mediated either through increased AR expression, amplification of the AR gene, or mutation-induced changes hormone responsiveness of the AR [67-69] contribute to ADT resistance.”
BackgroundMolina, A., & Belldegrun, A. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.042 · Cited by 112
Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells
Yang, X., Chen, M.-W., Terry, S., Vacherot, F., Bemis, D. L., Capodice, J. L., Kitajewski, J., TAILLE, A. D. L., Benson, M. C., Guo, Y., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209366 · Cited by 122
“Increasing evidence also indicates that the Wnt signaling pathway plays a role in PCa, especially in progression to the most aggressive and therapeutic-resistant state (de la Taille et al., 2003; Chen et al., 2004b).”
BackgroundResultDehm, S. M., & Tindall, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605002200 · Cited by 113
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
Kahn, B., Collazo, J., & Kyprianou, N. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8671 · Cited by 121
“discovered partial agonist characteristics of anti-androgens sufficient to activate the AR in the setting of AR overexpression secondary to changes in coactivator recruitment to the AR promoter region (rather than AR gene mutations)[44, 49].”
BackgroundHu, Y., Sun, H., Owens, R. T., Wu, J., Chen, Y. Q., Berquin, I. M., Perry, D. L., O’Flaherty, J. T., & Edwards, I. J. (2009) · Neoplasia · doi:10.1593/neo.09760 · Cited by 119
“Discussion Androgen-independent progression of prostate cancer does not seem to involve AR loss but instead results from inappropriate activation of AR [39,40].”
BackgroundExpression of Androgen Receptor Is Negatively Regulated By p53
Alimirah, F., Panchanathan, R., Chen, J., Zhang, X., Ho, S.-M., & Choubey, D. (2007) · Neoplasia · doi:10.1593/neo.07769 · Cited by 108
“Importantly, studies have provided evidence that a modest increase in AR mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy [4,6].”
BackgroundInfluentialLange, C. A., Gioeli, D., Hammes, S. R., & Marker, P. C. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.160319 · Cited by 110
NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice
Jin, R. J., Wang, Y., Masumori, N., Ishii, K., Tsukamoto, T., Shappell, S. B., Hayward, S. W., Kasper, S., & Matusik, R. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3117 · Cited by 111
“Because an increase in AR level has been reported to be sufficient to account for hormone refractory prostate cancers (15, 16), the NE cell population ability to increase AR level/activity can be another mechanism that allows prostate cancer to escape androgen ablation therapy.”
Periyasamy, S., Hinds, T., Shemshedini, L., Shou, W., & Sanchez, E. R. (2010) · Oncogene · doi:10.1038/onc.2009.458 · Cited by 108
Yang, Y. C., Banuelos, C. A., Mawji, N. R., Wang, J., Kato, M., Haile, S., McEwan, I. J., Plymate, S. R., & Sadar, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2901 · Cited by 118
“There are several possible mechanisms underlying continued transactivation of AR, including amplification of AR (3), gain-offunction mutations within the ligand-binding domain (LBD) of AR that enables activation by nonandrogenic steroids or antiandrogens (4, 5), ligand-independent activation of the AR N-terminus domai…”
BackgroundDiscovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M.-M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 106
Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer
Kallifatidis, G., Hoy, J. J., & Lokeshwar, B. L. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.06.003 · Cited by 118
Identification of novel androgen receptor target genes in prostate cancer
Jariwala, U., Prescott, J., Li, J., Barski, A., Pregizer, S., Cogan, J. P., Arasheben, A., Tilley, W. D., Scher, H. I., Gerald, W. L., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-39 · Cited by 119
Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106
Castration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Geraniol inhibits prostate cancer growth by targeting cell cycle and apoptosis pathways
Kim, S.-H., Bae, H. C., Park, E., Lee, C. R., Kim, B.-J., Lee, S., Park, H. H., Kim, S. J., So, I., Kim, T., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.124 · Cited by 119
Androgen signaling and its interactions with other signaling pathways in prostate cancer
Kaarbø, M., Klokk, T. I., & Saatcioglu, F. (2007) · BioEssays · doi:10.1002/bies.20676 · Cited by 126
“Recent studies also indicate that AR signaling has a major role in advanced prostate cancer, which is hormone refractory or androgen independent.((5)) At this stage, even though the levels of circulating androgens are low, through various mechanisms, such as amplification of the AR gene and upregulation of AR (1)Depar…”
BackgroundTakayama, K., Kaneshiro, K., Tsutsumi, S., Horie‐Inoue, K., Ikeda, K., Urano, T., Ijichi, N., Ouchi, Y., Shirahige, K., Aburatani, H., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210229 · Cited by 110
“Indeed, a modest increase in AR mRNA has been shown to be associated with the resistance to anti-androgen therapy in isogenic prostate cancer xenograft models (Chen et al., 2004).”
BackgroundProstate epithelial stem cells
Rizzo, S., Attard, G., & Hudson, D. L. (2005) · Cell Proliferation · doi:10.1111/j.1365-2184.2005.00356.x · Cited by 121
Takayama, K., Tsutsumi, S., Katayama, S., Okayama, T., Horie‐Inoue, K., Ikeda, K., Urano, T., Kawazu, C., Hasegawa, A., Ikeo, K., et al. (2010) · Oncogene · doi:10.1038/onc.2010.436 · Cited by 114
“It has been shown that AR and its downstream signals are deeply involved in the pathophysiology of hormone-dependent and hormone-independent PCas (Suzuki et al., 2003; Chen et al., 2004; Debes and Tindall, 2004).”
Targeting CYP17: established and novel approaches in prostate cancer
Yap, T. A., Carden, C. P., Attard, G., & Bono, J. S. D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.004 · Cited by 115
Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor
Zhou, X. E., Suino-Powell, K. M., Li, J., He, Y., MacKeigan, J. P., Melcher, K., Yong, E.-L., & Xu, H. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085779 · Cited by 106
In vitro model systems to study androgen receptor signaling in prostate cancer
Sampson, N., Neuwirt, H., Puhr, M., Klocker, H., & Eder, I. E. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0401 · Cited by 124
“PCa and CR-PCa remain largely dependent on the AR for growth (Chen et al. 2004).”
BackgroundInfluentialAilanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
He, Y., Peng, S., Wang, J., Chen, H., Cong, X., Chen, A., Hu, M., Qin, M., Wu, H., Gao, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms13122 · Cited by 113
Takayama, K.-I., Suzuki, T., Fujimura, T., Takahashi, S., & Inoue, S. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0471 · Cited by 104
“Although androgen deprivation therapy is initially effective for hormone-sensitive cancers, long-term treatment often results in castration-resistant prostate cancer (CRPC) with enhanced AR signaling (13, 15).”
BackgroundShiota, M., Yokomizo, A., & Naito, S. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-11-0018 · Cited by 114
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 116
“Notably, these studies have focused on AR binding events in the presence of androgen [typically after 10 nM 5a-dihydrotestosterone (DHT) treatment], based on the notion that CRPC growth depends on incomplete androgen suppression and continuous ligand-dependent activation of amplified or hypersensitive AR (6,25,26).”
BackgroundPurushottamachar, P., Godbole, A. M., Gediya, L. K., Martin, M. S., Vasaitis, T. S., Kwegyir‐Afful, A. K., Ramalingam, S., Ateş‐Alagöz, Z., & Njar, V. C. O. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400048v · Cited by 115
Prostate cancer-associated lncRNAs
Mitobe, Y., Takayama, K., Horie‐Inoue, K., & Inoue, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.012 · Cited by 113
Zhu, Y., Dalrymple, S. L., Coleman, I. M., Zheng, S. L., Xu, J., Hooper, J. E., Antonarakis, E. S., Marzo, A. M. D., Meeker, A. K., Nelson, P. S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01479-6 · Cited by 114
Qiao, Y., Choi, J. E., Tien, J. C.-Y., Simko, S. A., Rajendiran, T. M., Vo, J. N., Delekta, A. D., Wang, L., Xiao, L., Hodge, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00237-1 · Cited by 114
Bhuiyan, M. M. R., Li, Y., Banerjee, S., Ahmed, F., Wang, Z. P., Ali, S. S., & Sarkar, F. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2011 · Cited by 104
RetractedNon-competitive androgen receptor inhibition in vitro and in vivo
Jones, J. O., Bolton, E. C., Huang, Y., Feau, C., Guy, R. K., Yamamoto, K. R., Hann, B., & Diamond, M. I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807282106 · Cited by 104
“AR signaling also drives the proliferation of prostate cancer, even in the setting of therapies that reduce systemic hormone ligand levels, making AR the major therapeutic target for this malignancy (3).”
BackgroundInfluentialInhibition of androgen receptor and β-catenin activity in prostate cancer
Lee, E., Madar, A., David, G., Garabedian, M. J., DasGupta, R., & Logan, S. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218168110 · Cited by 120
“Androgen receptor (AR) up-regulation is the major determinate in CRPC (1), but conventional anti-androgen drugs fail to block AR activity in CRPCs where they can gain partial AR agonist properties (1).”
BackgroundInfluentialChiu, F., & Lin, J. (2007) · The Prostate · doi:10.1002/pros.20690 · Cited by 103
“Animal experiments have also demonstrated that increased AR expression effectively transforms prostate cancer growth from a hormone-sensitive to a hormone-refractory form, thereby causing AR antagonists to function as weak agonists, resulting in AR activation [8].”
BackgroundMembrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer
Freeman, M. R., Cinar, B., & Lu, M. L. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.06.002 · Cited by 116
Androgen axis in prostate cancer.
Culig, Z., & Bartsch, G. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20898 · Cited by 102
“An important question regarding the requirement of the AR for tumor progression was addressed by Sawyers’ group [Chen et al., 2004].”
BackgroundProgression of prostate cancer: Multiple pathways to androgen independence
Devlin, H.-L., & Mudryj, M. M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.007 · Cited by 108
Murga, J. D., Moorji, S. M., Han, A. Q., Magargal, W. W., DiPippo, V. A., & Olson, W. C. (2015) · The Prostate · doi:10.1002/pros.22910 · Cited by 102
“Finally, several PSMA-expressing lines are available as well-characterized patient-derived xenografts [41,42].”
BackgroundKang, B. H., Siegelin, M. D., Plescia, J., Raskett, C. M., Garlick, D. S., Dohi, T., Lian, J. B., Stein, G. S., Languino, L. R., & Altieri, D. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1818 · Cited by 104
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.